Literature DB >> 30904466

In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration.

Winnie T P Wan1, Yarmarly Guerra Valero2, Gordon Y S Choi3, Jenny L Ordóñez Mejia4, Steven C Wallis5, Gavin M Joynt6, Jeffrey Lipman7, Charles D Gomersall8, Jason A Roberts9.   

Abstract

There are very limited data on ticarcillin-clavulanate elimination by haemofiltration. We measured in vitro ticarcillin-clavulanate adsorption to polyacrylonitrile (PAN) filters and the sieving coefficient using a well-described bench model of haemofiltration. The dose of ticarcillin-clavulanate was 60/2 mg or 180/3 mg, and 0 or 12 g albumin was added to the 1 L of circulating blood-crystalloid mixture to produce four different experimental conditions. The experiment was repeated four times under each condition. Median (interquartile range [IQR] ) ticarcillin adsorption varied from 28 (27-30) mg to 85 (78-90) mg. Adsorption was increased when the dose of ticarcillin was higher (P<0.001), but was not affected by the addition of albumin. Median (IQR) adsorption of clavulanate ranged from 0.67 (0.55-0.75) mg to 1.8 (0.33-3.5) mg and was neither dose dependent (P = 0.505) nor significantly affected by the addition of albumin. Median (IQR) ticarcillin sieving coefficient ranged from 0.73 (0.67-0.75) to 0.99 (0.97-1.03). It was significantly higher with a higher dose of ticarcillin (P = 0.021) and without addition of albumin (P = 0.015). Median (IQR) clavulanate sieving coefficient ranged from 1.03 (1.00-2.24) to 2.0 (1.98-2.47). Clavulanate sieving coefficient was not significantly affected by dose or the addition of albumin. These data indicate that significant adsorption of both ticarcillin and clavulanate occurs in vitro; however, this requires confirmation by clinical pharmacokinetic studies. The sieving coefficient data may help guide appropriate dosing of critically ill patients receiving haemofiltration until more extensive clinical pharmacokinetic data are available.
Copyright © 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Clavulanic acid; Critical illness; Pharmacokinetics; Renal replacement therapy; Ticarcillin

Mesh:

Substances:

Year:  2019        PMID: 30904466     DOI: 10.1016/j.ijantimicag.2019.03.018

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

1.  An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy.

Authors:  Astrid Broeker; Matthias G Vossen; Florian Thalhammer; Steven C Wallis; Jeffrey Lipman; Jason A Roberts; Sebastian G Wicha
Journal:  Pharm Res       Date:  2020-05-14       Impact factor: 4.200

2.  Adsorption of vancomycin, gentamycin, ciprofloxacin and tygecycline on the filters in continuous renal replacement therapy circuits: in full blood in vitro study.

Authors:  Dariusz Onichimowski; Krzysztof Nosek; Hubert Ziółkowski; Jerzy Jaroszewski; Aleksandra Pawlos; Mirosław Czuczwar
Journal:  J Artif Organs       Date:  2020-10-08       Impact factor: 1.731

3.  Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy.

Authors:  Lauren Andrews; Scott Benken; Xing Tan; Eric Wenzler
Journal:  BMC Nephrol       Date:  2021-01-30       Impact factor: 2.388

4.  Determination and pharmacokinetic analysis of ticarcillin disodium-clavulanate potassium for injection in rat plasma by UPLC-ESI-MS/MS.

Authors:  Moli Wang; Yanxia Gao; Xueli Liu; Jing Zhang; Qiang Wang; Junshan Chang; Lantong Zhang
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.